Abstract
Huntington’s disease (HD) is an autosomal dominant progressive neurological disorder characterized by motor, cognitive, and psychiatric symptoms that typically present later on in life, although juvenile cases do exist. The identification of the disease-causing mutation, a CAG triplet repeat expansion in the HTT gene, in 1993 generated numerous investigations into the cellular and molecular pathways underlying the disorder. HD mouse models have played a prominent role in these studies, and the use of these mouse models of HD in the development and evaluation of novel therapeutic strategies is reviewed in this chapter. As new interventions and therapeutic approaches are evaluated and implemented, genetic mouse models will continue to be used with the hope of developing effective treatments for HD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pringsheim T, Wiltshire K, Day L et al (2012) The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord 27:1083–1091
Rawlins MD, Wexler NS, Wexler AR et al (2016) The prevalence of Huntington’s disease. Neuroepidemiology 46(2):144–153
Fisher ER, Hayden MR (2014) Multisource ascertainment of Huntington’s disease in Canada: prevalence and population at risk. Mov Disord 29(1):105–114
Gusella JF, Wexler NS, Conneally PM et al (1983) A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 306(5940):234–238
Anon et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell 72(6):971–983
Gama Sosa MA, De Gasperi R, Elder GA (2012) Modeling human neurodegenerative diseases in transgenic systems. Hum Genet 131(4):535–563
Wagner LA, Menalled L, Goumeniouk A et al (2008) Chapter 6: Huntington’s disease. In MacArthur, RA and Borsini F (eds.): Animal and Translational Models for CNS Drug Discovery: Neurological Disorders pp 207–266
Harper B (2005) Huntington disease (online). Available from: https://doi.org/10.1258/jrsm.98.12.550
Young AB, Shoulson I, Penney JB et al (1986) Huntington’s disease in Venezuela: neurologic features and functional decline. Neurology 36(2):244–249
Nance MA, Myers RH (2001) Juvenile onset Huntington’s disease: clinical and research perspectives. Ment Retard Dev Disabil Res Rev 7(3):153–157
Butters N, Wolfe J, Martone M et al (1985) Memory disorders associated with Huntington’s disease: verbal recall, verbal recognition and procedural memory. Neuropsychologia 23(6):729–743
Zakzanis KK (1998) The subcortical dementia of Huntington’s disease. J Clin Exp Neuropsychol 20(4):565–578
Anderson KE, Marder KS (2001) An overview of psychiatric symptoms in Huntington’s disease. Curr Psychiatry Rep 3(5):379–388
Lovestone S, Hodgson S, Sham P et al (1996) Familial psychiatric presentation of Huntington’s disease. J Med Genet 33(2):128–131
Sanberg PR, Fibiger HC, Mark RF et al (1981) Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Aust 1(8):407–409
Morton AJ, Wood NI, Hastings MH et al (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington’s disease. J Neurosci 25(1):157–163
Van Raamsdonk JM, Murphy Z, Selva DM et al (2007) Testicular degeneration in Huntington disease. Neurobiol Dis 26(3):512–520
Sharp AH, Loev SJ, Schilling G et al (1995) Widespread expression of Huntington’s disease gene (IT15) protein product. Neuron 14(5):1065–1074
Andrew SE, Goldberg YP, Kremer B et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 4(4):398–403
Mahadevan M, Tsilfidis C, Sabourin L et al (1992) Mytonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 225(5049):1235–1255
Semaka A, Creighton S, Warby S, Hayden MR et al (2006) Predictive testing for Huntingons disease: interpretation and significance of intermediate alleles. Clin Genet 70(4):283–294
Telenius H, Kremer HP, Theilmann J et al (1993) Molecular analysis of juvenile Huntington’s disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet 2(10):1535–1540
Becanovic K, Norremolle A, Neal SJ et al (2015) A SNP in the HTT promoter alters NF-kB binding and is a bidirectional genetic modifier of Huntington’s disease. Nat Neurosci 18(6):807–816
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium (2015) Identification of genetic factors that modify clinical onset of Huntington’s disease. Cell 162(3):516–526
Vonsattel JP, DiFiglia M (1998) Huntington’s disease. J Neuropathol Exp Neurol 57(5):369–384
Vonsattel JP, Myers RH, Stevens TJ et al (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44(6):559–577
Davies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90(3):537–548
DiFiglia M, Sapp E, Chase KO et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuritis in brain. Science 277(5334):1990–1993
Coyle JT, Schwarcz R (1976) Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea. Nature 263(5574):244–246
Beal MF, Ferrante RJ, Swartz KJ, Kowall NW (1991) Chronic quinolinic acid lesions in rats closely resemble Huntingtons-disease. J Neurosci 11(6):1649–1659
Ludolph AC, He F, Spencer PS et al (1991) 3-Nitropropionic acid – exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18(4):492–498
Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493–506
Carter RJ, Lione LA, Humby T et al (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci 19(8):3248–3257
Li JY, Popovic N, Brundin P et al (2005) The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies. NeuroRx 2(3):447–464
Schilling G, Becher MW, Sharp AH et al (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8(3):397–407
Luthi-Carter R, Strand A, Peters NL et al (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington’s disease. Hum Mol Genet 9(9):1259–1271
Andreassen OA, Dedeoglu A, Ferrante RJ et al (2001) Creatine increase survival and delays motor symptoms in transgenic animal model of Huntington’s disease. Neurobiol Dis 8(3):479–491
Andreassen OA, Ferrante RJ, Huang HM et al (2001) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington’s disease. Ann Neurol 50(1):112–117
Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF et al (2001) Lipoic acid improves survival in transgenic mouse models of Huntington’s disease. Neuroreport 12(15):3371–3373
Schilling G, Coonfield ML, Ross CA, Borchelt DR et al (2001) Coenzyme Q1 and remacemide hydrochloride ameloriate motor deficits in Huntington’s disease transgenic mouse model. Neurosci Lett 315(3):149–153
Slow EJ, Graham RK, Osmand AP et al (2005) Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A 102(32):11402–11407
Reddy PH, Charles V, Williams M et al (1999) Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington’s disease. Philos Trans R Soc Lond Ser B Biol Sci 354(1386):1035–1045
Tanaka Y, Igarashi S, Nakamura M et al (2006) Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol Dis 21(2):381–391
Hodgson JG, Agopyan N, Gutekunst CA et al (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23(1):181–192
Slow EJ, van Raamsdonk J, Rogers D et al (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12(13):1555–1567
Van Raamsdonk JM, Pearson J, Slow EJ et al (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington’s disease. J Neurosci 25(16):4169–4180. https://doi.org/10.1523/JNEUROSCI.0590-05.2005
Gray M, Shirasaki DI, Cepeda C et al (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28(24):6182–6195. https://doi.org/10.1523/JNEUROSCI.0857-08.2008
Barnes GT, Duyao MP, Ambrose CM et al (1994) Mouse Huntingtons-disease gene homology (Hdh). Somat Cell Mol Genet 20(2):87–94
White JK, Auerbach W, Duyao MP et al (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington’s disease CAG expansion. Nat Genet 17(4):404–410
Levine MS, Klapstein GJ, Koppel A et al (1999) Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington’s disease. J Neurosci Res 58(4):515–532
Lin CH, Tallaksen-Greene S, Chien WM et al (2001) Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet 10(2):137–144
Shelbourne PF, Killeen N, Hevner RF et al (1999) A Huntington’s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 8(5):763–774
Wheeler VC, White JK, Gutekunst CA et al (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in Hdh(Q92) and Hdh(Q111) knock-in mice. Hum Mol Genet 9(4):503–513
Menalled LB, Sison JD, Dragatsis I et al (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats. J Comp Neurol 465(1):11–26
Heng MY, Duong DK, Albin RL et al (2010) Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet 19(19):3702–3720. https://doi.org/10.1093/hmg/ddq285
Heng MY, Detloff PJ, Paulson HL, Albin RL (2010) Early alterations of autophagy in Huntington disease-like mice. Autophagy 6(8):1206–1208
Squitieri F, Gellera C, Cannella M et al (2003) Homozygosity for CAG mutation in Huntington disease is associated with more severe clinical course. Brain 126:946–955
Menalled LB, Kudwa AE, Miller S et al (2012) Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS One 12(7):e49838. https://doi.org/10.1371/journal.pone.0049838. [Epub 2012 Dec 20]
Southwell AL, Smith-Dijak A, Kay C et al (2016) An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum Mol Genet. Jul 4. pii: ddw212 [Epub ahead of print]
Gaveriaux-Ruff C, Kieffer B (2007) Conditional gene targeting in the mouse nervous system: insights into brain function and diseases. Pharmacol Ther 113:619–634
Mazarei G, Leavitt BR (2014) Murine models of HD. In: Movement disorders: genetics and models, 2nd edn. Elsevier, Amsterdam, pp 533–546
Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101(1):57–66
Furth PA, St Onge L, Boger H et al (1994) Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A 91(20):9302–9306
Díaz-Hernández M, Torres-Peraza J, Salvatori-Abarca A et al (2005) Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington’s disease. J Neurosci 25(42):9773–9781
Bradford J, Shin JY, Roberts M et al (2009) Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 106(52):22480–22485. https://doi.org/10.1073/pnas.0911503106
Bradford J, Shin JY, Roberts M et al (2010) Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 285(14):10653–10661
Faideau M, Kim J, Cormier K et al (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 19(15):3053–3067
Molero AE, Arteaga-Bracho EE, Chen CH et al (2016) Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington’s disease. Proc Natl Acad Sci U S A 113(20):5736–5741
Southwell AL, Warby SC, Carroll JB et al (2013) A fully humanized transgenic mouse model of Huntington disease. Hum Mol Genet 22(1):18–34
Kolodziejczyk K, Parsons MP, Southwell AL et al (2014) Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease. PLoS One 9(4):e94562. https://doi.org/10.1371/journal.pone.0094562. eCollection 2014
Menalled L, Lutz C, Ramboz S et al (2014) A field guide to working with mouse models of Huntington’s disease. http://chdifoundation.org/a-field-guide-to-working-with-mouse-models-of-huntingtons-disease/
Weller A, Leguisamo AC, Towns L et al (2003) Maternal effects in infant and adult phenotypes of 5HT1A and 5HT1B receptor knockout mice. Dev Psychobiol 42:194–205
Brunner D, Buhot MC, Hen R, Hofer M (1999) Anxiety, motor activation and maternal infant interactions in 5HT1B knockout mice. Behav Neurosci 113(3):587–601
Hockly E, Cordery PM, Woodman B et al (2002) Environmental enrichment slows disease progression in R6/2 Huntington’s disease mice. Ann Neurol 51(2):235–242
Farley SJ, McKay BM, Disterhoft JF, Weiss C (2011) Reevaluating hippocampus dependent learning in FVB/N mice. Behav Neurosci 125(6):871–878
Schauwecker PE (2005) Susceptibility to excitotoxic and metabolic striatal neurodegeneration in the mouse is genotype dependent. Brain Res 1040:112–120
Van Raamsdonk JM, Metzler M, Slow E et al (2007) Phenotypic abnormalities in the YAC128 mouse model of Huntington’s disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 26:189–200
Orvoen S, Pla P, Gardier AM, Saudou F, David DJ (2012) Huntington’s disease knock-in male mice show specific anxiety-like behavior and altered neuronal maturation. Neurosci Lett 507:127–132
Aziz NA, van der Burg JM, Landwehrmeyer GB, Brunding P, Stijnen T, EHDI Study Group, Roos RA (2008) Weight loss in Huntington’s disease increases with higher CAG repeat number. Neurology 71(19):1506–1513. https://doi.org/10.1212/01.wnl.0000334276.09729.0e
Hamm RJ, Pike BR, O’Dell DM, Lyeth BG, Jenkins LW (1994) The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 11(2):187–196
Pallier PN, Drew CK, Morton AJ (2009) The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington’s disease are task-and-protocol dependent: influence of non-motor factors on locomotor function. Brain Res Bull 78:347–355
Hockly E (2003) Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull 61:469–479
Hickey MA, Gallant K, Gross GG, Levine MS, Chesselet MF (2005) Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 20(1):1–11
Craufurd D, Snowden J (2002) Neuropsychological and neuropsychiatric aspects of Huntington’s disease. In: Bates G, Harper PS, Jones L (eds) Huntington's disease, 3rd edn. Oxford University Press, Oxford, pp 62–94
Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11(1):47–60
Block F, Kunkel M, Schwarz M (1993) Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performance in rats. Neurosci Lett 149(2):126–128
Abada YS, Schreiber R, Ellebroek B (2013) Motor, emotional and cognitive deficits in adult BACHD mice: a model for Huntington’s disease. Behav Brain Res 238:243–251
File SE, Mahal A, Mangiarini L, Bates GP (1998) Striking changes in anxiety in Huntington’s disease transgenic mice. Brain Res 805:234–240
Baldo B, Paganetti P, Grueninger S et al (2012) TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington’s disease. Chem Biol 19:264–275
Sathasivam K, Lane A, Legleiter J et al (2010) Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington’s disease. Hum Mol Genet 19:65–78
Weiss WF, Hodgdon TK, Kaler EW, Lenhoff AM, Roberts CJ et al (2007) Nonnative protein polymers: structure, morphology, and relation to nucleation and growth. Biophys J 93:4392–4403
Bayram-Weston Z, Jones L, Dunnet SB, Brooks SP (2016) Comparison of mHTT antibodies in Huntington’s disease mouse models reveal specific binding profiles and steady state ubiquitin levels with disease development. PLoS One 11(15):e0155834. https://doi.org/10.1371/journal.pone.0155834
Labadorf A, Hoss AG, Lagomarsino V et al (2015) RNA sequence analysis of human Huntington disease brain reveals an extensive increase in inflammatory and developmental gene expression. PLoS One 11(7):e0160295. https://doi.org/10.1371/journal.pone.0160295
Miller JRC, Lo KK, Andre R et al (2016) RNA-Seq of Huntington’s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum Mol Genet 25(14):2893–2904. https://doi.org/10.1093/hmg/ddw142
Carroll JB, Lerch JP, Franicosi S et al (2011) Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiol Dis 43:257–265
Heikkinen T, Lehtimaki K, Vartiainen N et al (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS One 7:e50717
Hickey MA, Kosmalska A, Enayati J et al (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington’s disease mice. Neuroscience 157:280–295
Brunner D, Balci F, Ludvig EA (2012) Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration. Behav Process 89:187–195
Menalled LM, Brunner D (2014) Animal models of Huntington’s disease for translation to the clinic: best practices. Mov Disord 15(29):1375–1390. https://doi.org/10.1002/mds.26006
Wild E, Tabrizi SJ (2014) Targets for future clinical trials in Huntington’s disease: what’s in the pipeline? Mov Disord 29(11):1434–1445. https://doi.org/10.1002/mds.26007
Pavon-Agustin C, Mielcarek M, Canut-Garriga M, Isalan M (2016) Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol Neurodegener 11(1):64. https://doi.org/10.1186/s13024-016-0128-x
Garriga-Canut M, Agustin-Pavon C, Herrmann F et al (2012) Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A 109(45):E3136–E3145. https://doi.org/10.1073/pnas.1206506109
Dalston NA, Gonzalez-Barriga A, Kourkouta E et al (2017) The expanded CAG repeat in the huntingtin gene as a target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One 12(2):e0171127. https://doi.org/10.1371/journal.pone.0171127
Rue L, Coronel-Banez M, Muncunil-Creus J et al (2016) Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels. J Clin Invest 126(11):4319–4330. https://doi.org/10.1172/JCI83185
Monteys AM, Ebanks SA, Kesier MS, Davidson BL (2017) CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther 25(1):12–23. https://doi.org/10.1016/j-ymthe.2016.11.010
Kratter IH, Zahed H, Lau A et al (2016) Serine 421 regulates huntingtin toxicity and clearance in mice. J Clin Invest 126(9):3585–3597. https://doi.org/10.1172/JCI80339
Ochaba J, Monteys AM, O’Rourke JG et al (2016) PIAS1 regulates mutant huntingtin accumulation and Huntington’s disease-associated phenotypes in vivo. Neuron 90(3):507–520. https://doi.org/10.1016/j.neuron.2016.03.016
Lee JH, Tecedor L, Chen YH et al (2015) Reinstating aberrant mTORC1 activity in Huntington’s disease mice improves disease phenotype. Neuron 85(2):303–315. https://doi.org/10.1016/j.neuron.2014.12.019
Chopra V, Quinti L, Khanna P et al (2016) LBH589, a hydroxamic acid-derived HDAC inhibitor is neuroprotective in mouse models of Huntington’s disease. J Huntingtons Dis 5(4):347–355
Squitieri F, Di Pardo A, Favellato M, Amico E, Maglione V, Frati L (2015) Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. J Cell Mol Med 19(11):2540–2548. https://doi.org/10.1111/jcmm.12604
Geva M, Kusko R, Soares H et al (2016) Pridopidine activates neuroprotective pathways impaired in Huntington’s disease. Hum Mol Genet 25(18):3975–3987. https://doi.org/10.1093/hmg/ddw238
Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I (2017) The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington’s disease. Neurobiol Dis 97(Pt A):46–59. https://doi.org/10.1016/j.nbd.2016.10.006
Corey-Bloom J, Jia H, Aikin AM, Thomas EA (2014) Disease modifying potential of glatiramer acetate in Huntington’s disease. J Huntingtons Dis 3(3):311–316. https://doi.org/10.3233/JHD-140110
Imamura T, Fujita K, Tagawa K et al (2016) Identification of hepta-histidine as a candidate drug for Huntington’s disease by in silico-in vitro-in vivo-integrated screens of chemical libraries. Sci Rep 6:33861. https://doi.org/10.1038/srep33861
Garcia-Miralles M, Hong X, Tan JL et al (2016) Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioral improvements in the YAC128 model of Huntington’s disease. Sci Rep 6:31652. https://doi.org/10.1038/srep31652
Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Munoz E, Sagredo O (2015) Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 12(1):185–199. https://doi.org/10.1007/s133-014-0304-z
Diaz-Alonso J, Paraiso-Luna J, Navarrete C et al (2016) VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease. Sci Rep 6:29789. https://doi.org/10.1038/srep29789
Wright DJ, Renoir T, Smith ZM et al (2015) N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington’s disease. Transl Psychiatry 5:e492. https://doi.org/10.1038/tp.2014.131
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kosior, N., Leavitt, B.R. (2018). Murine Models of Huntington’s Disease for Evaluating Therapeutics. In: Precious, S., Rosser, A., Dunnett, S. (eds) Huntington’s Disease. Methods in Molecular Biology, vol 1780. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7825-0_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7825-0_10
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7824-3
Online ISBN: 978-1-4939-7825-0
eBook Packages: Springer Protocols